Epithelial-mesenchymal transitions and the intersecting cell fate of fibroblasts and metastatic cancer cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

1. An early-screening biomarker of endometrial carcinoma: NGAL is associated with epithelio-mesenchymal transition.Oncotarget · 2016
   Article
2. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model.The Journal of clinical investigation · 2010
   Article
3. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro.American journal of physiology. Lung cellular and molecular physiology · 2009
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as